drugset / Trial / NCT03149055
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Phase 2
Completed
99 enrolled
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).
Timeline
- Start
- 2017-05-04
- Primary completion
- 2019-08-20
- Completion
- 2021-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isavuconazole | Small molecule | 372 mg | Intravenous |